Should MRD Status be used as a good endpoint for drug approval?
Minimal Residual Disease results come from an extremely sensitive test that detects how many myeloma cells are left in your body after reaching at least a very good partial response from myeloma medications. Some researchers are now wanting to use MRD results as endpoints in clinical trials in order to accelerate drug approval. What are the pros and cons to this proposal? Dr. Syed Abbas Ali shares with us his thoughts on the subject. Come with your questions!
Audret introduces the agenda of the event and our featured speaker Dr. Syed Abbas Ali.
Dr. Syed Abbas Ali shares with us his thoughts on the subject.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Syed Abbas Ali, MBBS
Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health.